The CD40/CD40L system: a new therapeutic target for disease.
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhang, B; Wu, T; Chen, M; Zhou, Y; Yi, D; Guo, R
CD40 molecule, TNF receptor superfamily member 5
immune system disorder
immune system dysfunction
The role of CD40/CD40 ligand (CD40L) interactions in atherothrombosis, in the response of the immune system to pathogens and in thrombosis is now widely accepted. A role for CD40-CD40L interactions has been identified in atherosclerosis (AS), and such interactions are known to destabilize atherosclerotic plaques by inducing the expression of cytokines, chemokines, growth factors, matrix metalloproteinases and pro-coagulant factors. CD40/CD40L interactions have also been implicated in immune system disorders. Recent studies have suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. Here, we discuss the current drugs that target the CD40/CD40L system, as understanding the roles and regulations of CD40/CD40L-mediated signal pathways by these drugs could facilitate the development of therapeutics that target diverse diseases. Copyright © 2013 Elsevier B.V. All rights reserved.
Click on any component of the trees below to see articles for any topic that is a member of that